Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer

Objectives To observe the curative effects and adverse reactions of recombinant human (rh)‐endostatin injection combined with a TP regimen for treating patients with advanced ovarian cancer. Methods Fifty‐four patients with pathologically confirmed ovarian cancer were randomly divided into a combined treatment (intravenous pump of rh‐endostatin + TP regimen) group and a control (single chemotherapy) group, twenty‐seven patients in each group. All patients were given a conventional CT examination. The level of vascular endothelial growth factor (VEGF), the size of tumor before treatment, after 2 cycles and after 4 cycles of treatment were determined for the comparison of curative effects and adverse reactions. Results The effective rate was 37.0% (10/27) and disease control rate was 63.0% (17/27) in the combined treatment group after 2 cycles of treatment. The effective rate was 25.9% (7/27) and disease control rate was 63.0% (17/27) in the control group. The comparison between these two groups showed no significant differences ( P  > 0.05). The effective rate was 63.0% (17/27) and disease control rate was 92.6% (25/27) in the combined treatment group after 4 cycles of treatment. The effective rate was 29.6% (8/27) and disease control rate was 63.0% (17/27) in the control group. The effective rate and disease control rate between these two groups after 4 cycles of treatment showed significant differences ( P  < 0.05). The incidences of cardiovascular toxicity, myelosuppression, sore muscles and joints, alopecia and gastrointestinal reaction was not significantly different between two groups ( P  > 0.05). Conclusion The pump delivery of rh‐endostatin can down‐regulate the expression of VEGF in ovarian cancer and has the better curative effect and slighter adverse reactions.